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ardiac Resynchronization
or Asymptomatic or Mildly
ymptomatic Heart Failure
Bridge Too Far?*
hristophe Leclercq, MD, PHD,†
hilippe Mabo, MD,†
ean Noel Trochu, MD, PHD‡
ennes and Nantes, France
fter the demonstration, in controlled clinical trials, of
ignificant morbidity and mortality benefits conferred by
ardiac resynchronization therapy (CRT) in patients in New
ork Heart Association (NYHA) heart failure (HF) func-
ional class III or IV despite optimal medical management,
n sinus rhythm, and with a QRS duration 120 ms, the
ssue of whether CRT might be extended to other patient
opulations has been raised (1). In patients with advanced
F, mechanical dyssynchrony and a QRS 120 ms in
uration, preliminary results have been disappointing, perhaps
ecause, in this subset, CRT is ineffective, or perhaps the
pplication of standard criteria of mechanical dyssynchrony is
ot appropriate (2). In patients in NYHA functional class
III, the hypothetical objectives of CRT are to slow the
rogression of disease and lower the mortality related to
ts severity. The latter was examined in the REVERSE
REsynchronization reVErses Remodeling in Systolic Left
Entricular dysfunction) trial, the results of which are
resented by Linde et al. (3) in this issue of the Journal.
See page 1834
The REVERSE trial enrolled patients presenting with no
r mild manifestations of HF (American College of Cardi-
logy/American Heart Association stage C, NYHA func-
ional class I or II), despite optimal drug therapy, including
table doses of an angiotensin-converting enzyme inhibitor
Editorials published in the Journal of the American College of Cardiology reflect the
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eceived research grants from Medtronic and Sorin.r angiotensin I receptor blocker, and a beta-adrenergic
locker for 3 months. All patients were in sinus rhythm,
ith120-ms QRS duration, a40% left ventricular (LV)
jection fraction, and a55-mm LV end-diastolic diameter
easured by echocardiography. Among 684 enrolled pa-
ients, 610 were randomly assigned to CRT-ON (n  419)
ersus CRT-OFF (control group; n  191). The primary
nd point of the trial was an HF clinical composite
esponse, which, over a 12-month follow-up, classified
atients as worsened, unchanged, or improved. Because of
he inclusion of asymptomatic patients, the proportion of
orsened patients was used to compare the efficacy of CRT
etween the 2 study groups. The absolute change in left
entricular end-systolic volume index (LVESVI) between
aseline and 12 months of follow-up was a secondary end
oint adjudicated by 2 independent core echocardiographic
aboratories (3). No significant difference in the proportion
f worsened patients was observed between the 2 groups,
nd thus the primary end point did not reach the statistical
ignificance pre-specified in the trial protocol.
With regard to LVESVI, paired data were available in
nly 79% of the 610 randomly assigned patients (77% of
issing data), mainly because of technically unsatisfactory
aseline or follow-up echocardiograms. However, a signif-
cantly greater decrease in LVESVI was observed in the
RT-ON group than in the control group, and the decrease
n LVESVI was significantly greater among patients with
onischemic than among patients with ischemic heart
isease. No significant differences were observed between
he 2 groups with respect to NYHA functional class, quality
f life, or incidence of ventricular tachyarrhythmias. How-
ver, the time to first hospitalization for management of HF
as significantly longer in the CRT-ON than in the control
roup (hazard ratio: 0.47; p  0.03). Finally, the overall
ates of periprocedural and post-procedural or system-
elated complications were 4% and 16%, respectively.
It is noteworthy that 95% of patients included in the
EVERSE trial received an angiotensin-converting enzyme
nhibitor or an angiotensin I receptor blocker, and a beta-
drenergic blocker for 3 months, and that 60% received
50% of the target dose, and 30% the full target dose of
eta-adrenergic blocker. By comparison with the most recent
F trials and actual clinical practice, the pharmacological
anagement in the REVERSE trial was optimal (4,5). The
uality of drug therapy might explain, at least partially, the
onsiderably lower 1-year mortality rate observed in both
roups of the REVERSE trial than the 5.3% rate in the active
rm of the MERIT-HF (Metoprolol CR/XL Randomised
ntervention Trial in Congestive Heart Failure) study (6).
s CRT Ineffective in Asymptomatic
r Mildly Symptomatic Patients, and Will
t Never Be Indicated in This Population?
he REVERSE trial may be viewed as a “negative” trial
ecause of the primary end point outcome. Among several
p
t
c
a
w
s
T
a
p
w
w
a
t
p
m
o
d
t
i
H
s
t
a
f
l
A
t
o
I
(
v
w
M
v
t
a
v
p
t
(
h
i
t
i
m
e
f
m
r
o
i
t
b
(
F
m
c
S
C
l
r
p
p
y
p
l
r
y
c
T
r
t
s
T
t
s
i
y
w
e
p
i
t
t
e
f
l
R
S
P
3
c
R
1845JACC Vol. 52, No. 23, 2008 Leclercq et al.
December 2, 2008:1844–6 Cardiac Resynchronization and HFotential explanations for these results, the first might be
hat CRT is not effective in this population, though this
onclusion is probably premature. Second, the pre-specified
nalysis plan considered only changes in the proportion of
orsened patients (i.e., that unchanged or improved
tatuses indicated the absence of disease progression).
his is not how an HF composite score is usually
nalyzed (7). Typically, the analysis compares the pro-
ortion of unchanged, worsened, or improved patients
ithout combining criteria, in which case the difference
ould have significantly favored CRT-ON, since it was
ssociated with 54% of improved patients versus 40% in
he control group. However, the REVERSE trial was not
owered for this kind of analysis. A third explanation
ight be that the treatment effect requires a prolonged
bservation period, and that the HF clinical composite
id not detect a benefit at 1 year. Previous studies limited
o 6-month follow-ups have failed to show a clinical
mprovement conferred by CRT in patients in NYHA
F functional class II (8,9). It would, therefore, not be
urprising that a 1-year trial of CRT including asymp-
omatic patients was too short to demonstrate its efficacy,
nd that the primary end point and the duration of
ollow-up were both lacking, particularly in view of the
ow clinical event rate observed in the REVERSE trial.
n additional 1-year of follow-up has been planned for
he European cohort of the REVERSE trial, the results
f which are expected in early 2009.
As previously found in the MIRACLE (Multicenter
nSync Randomized Clinical Evaluation) and CARE-HF
Cardiac Resynchronization Heart Failure) trials, LV re-
erse remodeling is a major therapeutic effect of CRT,
hich increases over time (10,11). The CONTAK-CD and
IRACLE ICD (Multicenter InSync Implantable Cardio-
ersion Defibrillation Randomized Clinical Evaluation) II
rials have suggested similar benefits in patients with less
dvanced HF (8,9). The strong association between reverse
entricular remodeling and clinical outcomes in trials of
harmaceuticals supports the inclusion of measures of ven-
ricular volumes in the assessment of new treatments of HF
12). Moreover, in CRT system recipients, LV remodeling
as been correlated with longer survival by contrast to
mprovements in clinical status (13). In the REVERSE
rial, in addition to optimal treatment, CRT caused an
mpressive amount of reverse LV remodeling, of greater
agnitude among patients with nonischemic heart dis-
ase, as previously shown. The European population
ollowed over 24 months should provide valuable infor-
ation regarding the temporal evolution of the reverse
emodeling process that occurs during CRT. While the
bservations made with respect to time to first hospital-
zation for management of HF were largely encouraging,
he REVERSE trial was not powered to measure mor-
idity and mortality rates, unlike the ongoing RAFT
Resynchronization/defibrillation for Ambulatory heart
ailure Trial) and MADIT CRT (Multicenter Auto-atic Defibrillator Implantation Trial–Cardiac Resyn-
hronization Therapy) studies (14,15).
afety Issues
RT is an invasive treatment requiring the implantation of
eads and a pulse generator. The 97% implantation success
ate observed in the REVERSE trial is higher than in
revious studies (1). However, all medical centers partici-
ating in the trial had a long experience with, and a high
early rate of CRT system implantations, suggesting these
rocedures should be limited to referral centers of excel-
ence. Furthermore, the rate of LV lead dislodgement
equiring reoperation in the REVERSE trial was 8% at 1
ear and, as mentioned by the authors, the rates of compli-
ations should be definitively reascertained at 5 years (3).
his is mandatory to objectively measure the risk/benefit
atio, particularly in a population with mild HF.
In summary, the REVERSE trial showed, for the first
ime, significant reverse LV remodeling by CRT in mildly
ymptomatic patients who received optimal drug treatment.
his is a major and encouraging observation, especially in
his particular HF population. Unfortunately, and not
urprisingly, the REVERSE trial did not observe a clinical
mprovement conferred by CRT in this HF population at 1
ear, but we may reasonably expect a more positive result
ith the 2-year follow-up. These factors should be consid-
red in the completion of further clinical trials. The marked
rogress in the medical management of HF requires the
nclusion of large numbers of patients and long follow-ups
o confirm the clinical benefits conferred by supplemental
herapy in trials with low expected rates of adverse clinical
vents. Is the bridge of CRT in patients with mild HF too
ar? Probably yes for those who are rushed. Clinical trials,
ike countless valuable products, need to mature.
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